VIM and melanoma: Downregulation of both vimentin and nestin has been previously linked to drug resistance in melanoma, as well as upregulation of processes such as PI3K/AKT signaling, remodeling of focal adhesions, actin cytoskeleton, and integrin signaling (Schmitt et al., 2019).